Proteomics International Laboratories Ltd (ASX: PIQ), a leader in predictive diagnostics, has engaged Growth Medics B.V. to expand the reach of its PromarkerD test across Europe. This strategic partnership aims to recruit and manage new partners and customers, enhancing the market penetration of PromarkerD, a groundbreaking predictive test for diabetic kidney disease (DKD).
With over 61 million adults in Europe affected by type 2 diabetes, the need for innovative solutions like PromarkerD is critical. This collaboration is set to drive significant advancements in the early detection and prevention of DKD, ultimately aiming to improve patient outcomes and reduce healthcare costs.
Read the full article to learn more about this pivotal partnership and its implications for the European healthcare landscape.
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02817689-6A1211689
